Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
Background: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in progression-free survival and overall survival relative to mFOLFOX6 alone in previously untreated locally advanced or metastatic gastric or gastroes...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | ESMO Gastrointestinal Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949819824000566 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115382445080576 |
|---|---|
| author | Z.A. Wainberg P.C. Enzinger S. Qin K. Yamaguchi J. Wang X. Zhou A. Gnanasakthy K. Taylor A. Yusuf I. Majer A. Jamotte Y.-K. Kang |
| author_facet | Z.A. Wainberg P.C. Enzinger S. Qin K. Yamaguchi J. Wang X. Zhou A. Gnanasakthy K. Taylor A. Yusuf I. Majer A. Jamotte Y.-K. Kang |
| author_sort | Z.A. Wainberg |
| collection | DOAJ |
| description | Background: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in progression-free survival and overall survival relative to mFOLFOX6 alone in previously untreated locally advanced or metastatic gastric or gastroesophageal junction cancer with fibroblast growth factor receptor 2b overexpression. Using data from the final analysis, we analyzed patient-reported outcomes (PROs) to evaluate the impact of adding bemarituzumab to mFOLFOX6 on health-related quality of life (HRQoL). Materials and methods: Patients were randomized 1 : 1 to bemarituzumab plus mFOLFOX6 (n = 77) or placebo plus mFOLFOX (n = 78). European Organisation for Research and Treatment of Cancer Core 30-item Quality of Life (EORTC QLQ-C30) and the EuroQol EQ-5D-5L questionnaires were administered at baseline, week 6, every 8 weeks thereafter, and at end-of-treatment visit. Least-squares mean changes from baseline in PRO scale scores were estimated using mixed models for repeated measures; time to deterioration and improvement were assessed using Cox proportional hazards models. Analyses were exploratory post hoc. Results: PRO scale scores at baseline and compliance rates across PRO assessments over time were similar between the bemarituzumab and placebo arms. Least-squares mean changes from baseline on key EORTC QLQ-C30 scales (global health status/QoL, physical functioning, fatigue, nausea and vomiting, and appetite loss) and the EQ-5D-5L visual analog scale were similar over time between treatment arms. Analyses of time to deterioration, sustained deterioration, and improvement suggested similar HRQoL between treatment arms. Conclusions: Treatment with bemarituzumab plus mFOLFOX6 was associated with sustained HRQoL relative to mFOLFOX6 alone. |
| format | Article |
| id | doaj-art-d7f2350639094ea9bee87af46bc0a676 |
| institution | OA Journals |
| issn | 2949-8198 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | ESMO Gastrointestinal Oncology |
| spelling | doaj-art-d7f2350639094ea9bee87af46bc0a6762025-08-20T02:36:35ZengElsevierESMO Gastrointestinal Oncology2949-81982024-12-01610009510.1016/j.esmogo.2024.100095Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancerZ.A. Wainberg0P.C. Enzinger1S. Qin2K. Yamaguchi3J. Wang4X. Zhou5A. Gnanasakthy6K. Taylor7A. Yusuf8I. Majer9A. Jamotte10Y.-K. Kang11Department of Medicine, University of California Los Angeles Medical Center, Los AngelesDepartment of Medicine, Dana Farber Cancer Institute, Boston, USANanjing Tianyinshan Hospital, the 1st Affiliated Hospital of China Pharmaceutical University, Nanjing, ChinaGastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Koto-Ku, Tokyo, JapanRTI Health Solutions, Research Triangle Park, USARTI Health Solutions, Research Triangle Park, USARTI Health Solutions, Research Triangle Park, USAGlobal Biostatistics, Amgen Ltd., London, UKGlobal Medical Affairs, Amgen Inc., Thousand Oaks, USAGlobal HEOR, Amgen (Europe) GmbH, Rotkreuz, Switzerland; Correspondence to: Dr Istvan Majer, Amgen Europe GmbH, Suurstoffi 22, CH-6343, Rotkreuz, Switzerland. Tel: +41-41-369-01-12Global HEOR, Amgen (Europe) GmbH, Rotkreuz, SwitzerlandAsan Medical Centre, University of Ulsan College of Medicine, Seoul, South KoreaBackground: In the phase II, randomized, double-blind FIGHT trial (NCT03694522), treatment with bemarituzumab plus mFOLFOX6 resulted in improvements in progression-free survival and overall survival relative to mFOLFOX6 alone in previously untreated locally advanced or metastatic gastric or gastroesophageal junction cancer with fibroblast growth factor receptor 2b overexpression. Using data from the final analysis, we analyzed patient-reported outcomes (PROs) to evaluate the impact of adding bemarituzumab to mFOLFOX6 on health-related quality of life (HRQoL). Materials and methods: Patients were randomized 1 : 1 to bemarituzumab plus mFOLFOX6 (n = 77) or placebo plus mFOLFOX (n = 78). European Organisation for Research and Treatment of Cancer Core 30-item Quality of Life (EORTC QLQ-C30) and the EuroQol EQ-5D-5L questionnaires were administered at baseline, week 6, every 8 weeks thereafter, and at end-of-treatment visit. Least-squares mean changes from baseline in PRO scale scores were estimated using mixed models for repeated measures; time to deterioration and improvement were assessed using Cox proportional hazards models. Analyses were exploratory post hoc. Results: PRO scale scores at baseline and compliance rates across PRO assessments over time were similar between the bemarituzumab and placebo arms. Least-squares mean changes from baseline on key EORTC QLQ-C30 scales (global health status/QoL, physical functioning, fatigue, nausea and vomiting, and appetite loss) and the EQ-5D-5L visual analog scale were similar over time between treatment arms. Analyses of time to deterioration, sustained deterioration, and improvement suggested similar HRQoL between treatment arms. Conclusions: Treatment with bemarituzumab plus mFOLFOX6 was associated with sustained HRQoL relative to mFOLFOX6 alone.http://www.sciencedirect.com/science/article/pii/S2949819824000566bemarituzumabFGFR2bgastric cancerhealth-related quality of lifemFOLFOX6targeted therapy |
| spellingShingle | Z.A. Wainberg P.C. Enzinger S. Qin K. Yamaguchi J. Wang X. Zhou A. Gnanasakthy K. Taylor A. Yusuf I. Majer A. Jamotte Y.-K. Kang Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer ESMO Gastrointestinal Oncology bemarituzumab FGFR2b gastric cancer health-related quality of life mFOLFOX6 targeted therapy |
| title | Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer |
| title_full | Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer |
| title_fullStr | Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer |
| title_full_unstemmed | Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer |
| title_short | Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer |
| title_sort | health related quality of life with bemarituzumab plus mfolfox6 in patients with fgfr2b overexpressing advanced gastric or gastroesophageal junction cancer |
| topic | bemarituzumab FGFR2b gastric cancer health-related quality of life mFOLFOX6 targeted therapy |
| url | http://www.sciencedirect.com/science/article/pii/S2949819824000566 |
| work_keys_str_mv | AT zawainberg healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT pcenzinger healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT sqin healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT kyamaguchi healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT jwang healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT xzhou healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT agnanasakthy healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT ktaylor healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT ayusuf healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT imajer healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT ajamotte healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer AT ykkang healthrelatedqualityoflifewithbemarituzumabplusmfolfox6inpatientswithfgfr2boverexpressingadvancedgastricorgastroesophagealjunctioncancer |